Dr. Martine Extermann, MD

Dr. Extermann practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Extermann's NPI, 1154353589, was assigned on July 7, 2006. Dr. Extermann graduated from University of Geneva Faculty of Medicine in 1986. Dr. Extermann holds Florida license ME108695.

Dr. Extermann's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Extermann also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Extermann's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Extermann is also affiliated with Lee Memorial Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Extermann to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Extermann practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Extermann's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Extermann is board certified in internal medicine by the American Board of Internal Medicine. Dr. Extermann is licensed in Florida.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, lymphoma and prostate cancer among the conditions Dr. Extermann treats.

CMS data shows 597 Medicare services from Dr. Extermann across 5 procedure codes in 2024, all of them office visits, for 278 Medicare patients. Medicare paid $59,224 for them.

CMS counts 278 Medicare patients who saw Dr. Extermann in 2024. The largest group is 75 to 84, with 170 patients. 75% of them have cancer, and 75% have high blood pressure. 5% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Extermann's median patient age at 78, with 81% women.

In 2024, Dr. Extermann wrote 919 Medicare Part D claims for 226 patients. 78% of them were for generic drugs. CMS names the drug for 706 of them, across 20 drugs with 11 or more claims each, at $2,279,768 in total drug cost. In 2023, CMS named 539 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Extermann for performance year 2024, reported as part of a group. Dr. Extermann accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Extermann as offering telehealth.

Dmand AI links 150 papers to Dr. Extermann, published from 2003 to 2025. 2019 was the busiest year, with 9. The most frequent topics are Geriatric Assessment, Breast Neoplasms and Comorbidity. Dr. Extermann has published most often in J Geriatr Oncol. Dr. Extermann's most frequent co-authors are Lodovico Balducci, MD, Harvey J. Cohen, MD and Jeanne Mandelblatt, MD.

Dmand AI links Dr. Extermann to 11 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Breast Neoplasms, Male. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 8.

CMS Open Payments shows 8 general payments to Dr. Extermann from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Alnylam Pharmaceuticals Inc. paid the most, $4,095.

Dr. Extermann graduated from University of Geneva Faculty of Medicine in 1986. Dr. Extermann is a member of ACP, ASCO, International Society of Geriatric Oncology and SIOG.

Dr. Extermann is in network with 10 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.